Developments Kadmon Holdings completes enrollment for registrational GvHD trial Kadmon Holdings (NYSE:KDMN) completed enrollment for its registrational trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD). cGvHD is a deadly complication of hematopoietic stem cell... August 14, 2019